Company Overview - Onco3R Therapeutics is a clinical-stage immunology and oncology biotech company focused on transforming patients' lives with best-in-class medicines [1][6] - The company is based in Leuven, Belgium, and has over 150 years of combined R&D experience among its team [6] Leadership Appointment - Lawrence M. Blatt, PhD, MBA has been appointed as Chair of the Board of Directors [1] - Dr. Blatt has extensive experience in strategic leadership, drug development, and operations, previously serving as CEO of Aligos Therapeutics and holding key positions at Janssen Pharmaceutical Companies [2][3] Product Development - Onco3R is developing O3R-5671, a highly selective SIK3 inhibitor designed to treat autoimmune diseases while avoiding toxicities associated with SIK1 and SIK2 [4] - Preclinical data indicates that O3R-5671 can inhibit pro-inflammatory cytokines and promote immunomodulatory cytokines, suggesting its potential for treating conditions like ulcerative colitis, Crohn's Disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis [4] Clinical Trials - A Phase 1 trial for O3R-5671 is underway, evaluating its safety and pharmacokinetics in healthy volunteers, with plans for subsequent patient trials across various autoimmune diseases starting in 2026 [5]

Core Insights - Aligos Therapeutics, Inc. announced positive data from four presentations at the HEP-DART 2025 Meeting, showcasing advancements in therapies for liver and viral diseases [1][2] Pevifoscorvir Sodium Data - The Phase 1 monotherapy study of pevifoscorvir sodium for chronic hepatitis B virus (HBV) infection demonstrated its potential as a first-line therapy, with complete 96-week and post-treatment follow-up data indicating continued efficacy [3][6] ALG-055009 Data - New in vivo data from studies on diet-induced obese mice showed that the combination of ALG-055009 with incretin receptor agonists resulted in significant weight loss, with SEMA monotherapy achieving a maximum of 23.9% body weight loss, while the combination with ALG-055009 led to an additional 8.6% decrease for a total of 33% [4][5] - TIRZEP monotherapy resulted in a maximum of 27.1% and 34.4% body weight loss for low and high doses respectively, with combinations yielding up to 40% weight loss [4][5] Synergistic Effects - The combination therapy of ALG-055009 with incretin receptor agonists primarily resulted in fat mass loss without significantly affecting lean mass or food consumption, indicating a beneficial addition to existing therapies for weight loss [5][6] Future Directions - The company expressed enthusiasm for the potential of both pevifoscorvir sodium and ALG-055009, highlighting their commitment to advancing next-generation therapies for chronic HBV and metabolic diseases [6][9]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - SHF Holdings, Inc. (SHFS) increased by 150% to $8.17 - Lithium Americas Corp. (LAC) rose by 69% to $5.18 - Aqua Metals, Inc. (AQMS) gained 50% reaching $6.11 - CleanCore Solutions, Inc. (ZONE) up by 44% at $2.87 - Cyclerion Therapeutics, Inc. (CYCN) increased by 33% to $4.03 - Twin Vee Powercats Co. (VEEE) rose by 17% to $2.92 - Solidion Technology, Inc. (STI) up by 11% at $5.09 - China Pharma Holdings, Inc. (CPHI) increased by 11% to $2.18 - Stardust Power Inc. (SDST) rose by 10% to $3.04 - Aligos Therapeutics, Inc. (ALGS) increased by 7% to $11.03 [3] Premarket Losers - Aytu BioPharma, Inc. (AYTU) decreased by 15% to $2.11 - Professional Diversity Network, Inc. (IPDN) down by 13% to $4.10 - STRATA Skin Sciences, Inc. (SSKN) fell by 10% to $2.31 - Cohu, Inc. (COHU) decreased by 9% to $20.68 - Super League Enterprise, Inc. (SLE) down by 9% to $7.74 - CTW Cayman (CTW) fell by 9% to $2.29 - Fitell Corporation (FTEL) decreased by 8% to $7.70 - Soluna Holdings, Inc. (SLNH) down by 8% to $2.16 - StableX Technologies, Inc. (SBLX) decreased by 5% to $5.22 - Indaptus Therapeutics, Inc. (INDP) down by 5% to $2.95 [4]

Core Insights - Sanofi has received FDA approval for Wayrilz (rilzabrutinib), marking it as the first BTK inhibitor approved for treating persistent or chronic immune thrombocytopenia (ITP) in the United States [1][7] - The approval was based on the phase III LUNA 3 study, which demonstrated positive outcomes in sustained platelet counts and ITP symptoms, achieving both primary and secondary endpoints [2][7] - Wayrilz is also under review in the EU and China for ITP treatment and has been recently approved in the UAE for the same indication [3] Company Developments - Patients using Wayrilz will benefit from Sanofi's HemAssist program, which offers support for treatments related to rare blood disorders [3] - In addition to ITP, Wayrilz is being developed for other rare diseases, including IgG4-related disease (IgG4-RD) and warm autoimmune hemolytic anemia (wAIHA), with orphan drug designations from the FDA [5][9] - A phase II study is currently evaluating Wayrilz for IgG4-RD, a chronic immune-mediated condition affecting multiple organs [8] Stock Performance - Sanofi's shares have increased by 2.6% this year, contrasting with a 0.6% decline in the industry [4]

Core Viewpoint - Rocket Pharmaceuticals' shares increased by 28.9% after the FDA lifted the clinical hold on its pivotal phase II study for RP-A501, a gene therapy for Danon disease [1][7]. Group 1: Clinical Study Updates - The clinical hold was imposed in May due to a serious adverse event resulting in a patient's death, prompting the company to pause dosing [2]. - The FDA has now allowed the study to resume with a recalibrated lower dose of RP-A501 (3.8 x 10¹³ GC/kg), administered to three patients sequentially with a minimum four-week interval [3]. - Six patients have been treated in the pivotal phase II study, with further updates expected after reviewing data from the next three patients [4]. Group 2: Company Focus and Pipeline - Rocket Pharmaceuticals is prioritizing the development of adeno-associated virus (AAV) gene therapies for rare cardiovascular conditions, with RP-A501 being the most advanced candidate [8]. - The company is also developing another AAV-based candidate, RP-A601, for arrhythmogenic cardiomyopathy, and plans to initiate clinical studies for RP-A701 targeting dilated cardiomyopathy [10]. Group 3: Market Performance - Rocket Pharmaceuticals' shares have declined by 70.2% year-to-date, contrasting with a 3% rise in the industry [5].

Core Insights - Aligos Therapeutics, Inc. has appointed Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs, effective immediately, to enhance its leadership team during the development of ALG-000184 [1][2] - Dr. Polo brings extensive regulatory expertise from his previous roles at Shionogi Inc. and Johnson & Johnson, where he managed global regulatory strategies and played a key role in the COVID-19 vaccine rollout [2][3] - Aligos is focused on developing therapies for liver and viral diseases, with a pipeline targeting unmet medical needs such as chronic hepatitis B virus infection and metabolic dysfunction-associated steatohepatitis [3] Company Overview - Aligos Therapeutics, Inc. is a clinical stage biotechnology company dedicated to improving patient outcomes through innovative therapies for liver and viral diseases [3] - The company employs a science-driven approach and has a robust R&D pipeline aimed at addressing significant medical needs [3]

Core Insights - Allogene Therapeutics reported a narrower loss of 23 cents per share for Q2 2025, compared to the Zacks Consensus Estimate of a loss of 28 cents and a loss of 35 cents per share in the same period last year [2][3][6] - The company currently has no marketed products, resulting in no sales reported during the quarter [2][6] - Allogene's R&D expenses decreased by 20.2% year-over-year to $40.2 million, while G&A expenses fell by 11.2% to $14.3 million [3][6] - As of June 30, 2025, Allogene had $302.6 million in cash and equivalents, down from $335.5 million at the end of Q1 2025 [3] - Year-to-date, Allogene's shares have dropped 51.2%, contrasting with a 0.5% rise in the industry [3] Financial Guidance - The company anticipates operating expenses for 2025 to be around $230 million, with a projected cash burn of approximately $150 million [5][6] - Allogene claims that its current cash runway will support operations into the second half of 2027 based on these projections [5] Pipeline Developments - Allogene is advancing its CAR T pipeline, including the pivotal ALPHA3 study for cema-cel as a first-line treatment for large B cell lymphoma, with futility analysis expected in the first half of 2026 [8][10] - The company has initiated the phase I RESOLUTION study for ALLO-329, targeting various autoimmune diseases, with updates expected in the first half of 2026 [10] - ALLO-316, the first CAR T candidate for solid tumors, is being evaluated in the phase I TRAVERSE study, showing early anti-tumor activity [11][12] Strategic Initiatives - Earlier in the year, Allogene implemented cost realignment initiatives to optimize operations and extend its financial runway [7]

Core Viewpoint - Aligos Therapeutics, Inc. has announced that eight abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2025, highlighting its focus on innovative therapies for liver and viral diseases [1]. Group 1: Abstracts on Chronic Hepatitis B Virus (HBV) - Abstract 861 discusses the monotherapy with the novel capsid assembly modulator ALG-000184, showing profound and sustained HBV DNA suppression in untreated subjects over 96 weeks [2]. - Abstract 856 presents the safety and antiviral effect of oral daily 300 mg ALG-000184 in combination with Entecavir for untreated HBeAg-positive subjects, also over 96 weeks [3]. - Abstract 1924 reveals a high barrier of resistance to ALG-000184 based on viral kinetics and sequence analysis from a phase I monotherapy study [3]. Group 2: Abstracts on Metabolic Dysfunction-Associated Steatohepatitis (MASH) - Abstract 302 highlights that ALG-055009, a novel thyroid hormone receptor beta agonist, significantly reduces atherogenic lipids/lipoproteins in patients with presumed MASH in the Phase 2a HERALD study [4]. - Abstract 2185 indicates robust reductions in liver fat at Week 12 across subgroups, including GLP-1 receptor agonist users in non-cirrhotic MASH patients [4]. - Abstract 2152 discusses population pharmacokinetic/pharmacodynamic modeling of ALG-055009, showing a statistically significant correlation between exposure and key efficacy endpoints [5]. Group 3: Preclinical Research - Abstract 2105 presents next-generation hepatitis B virus antisense oligonucleotides with significantly improved properties compared to current clinical candidates [6]. Company Overview - Aligos Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing best-in-class therapies for liver and viral diseases, leveraging its R&D expertise to address high unmet medical needs [6].